Home/Filings/8-K/0001829126-26-000023
8-K//Current report

KALA BIO, Inc. 8-K

Accession 0001829126-26-000023

$KALACIK 0001479419operating

Filed

Jan 1, 7:00 PM ET

Accepted

Jan 2, 4:15 PM ET

Size

186.2 KB

Accession

0001829126-26-000023

Research Summary

AI-generated summary of this filing

Updated

Kala Bio, Inc. Settles Loan — Pays $2M to Oxford Finance

What Happened
Kala Bio, Inc. (KALA) reported in an 8-K that it paid $2.0 million to Oxford Finance, LLC on December 26, 2025 under a previously disclosed Loan Settlement Agreement. The Settlement Agreement related to defaults under a Loan and Security Agreement dated May 4, 2021. With this payment, Kala Bio says all obligations under the Settlement Agreement and the Loan Agreement have been satisfied and the aggregate liability to Oxford of approximately $10.6 million has been settled and released.

Key Details

  • Payment date: December 26, 2025.
  • Cash paid: $2.0 million to Oxford Finance, LLC.
  • Agreements involved: Loan Settlement Agreement and Loan and Security Agreement (dated May 4, 2021).
  • Total liability released: approximately $10.6 million.

Why It Matters
This filing confirms Kala Bio has resolved its outstanding obligations to Oxford and removed the lender’s claim tied to the previously disclosed defaults. For investors, the payment and release of the ~$10.6M liability reduces creditor exposure tied to these agreements and clarifies one source of legal/financial risk. The 8-K does not disclose how the payment was funded or any broader impact on the company’s cash position or operations.